Financials data is unavailable for this security.
View more
Year on year Supernus Pharmaceuticals Inc grew revenues 8.94% from 607.52m to 661.82m while net income improved 5,512.84% from 1.32m to 73.87m.
Gross margin | 89.57% |
---|---|
Net profit margin | 11.16% |
Operating margin | 12.34% |
Return on assets | 5.58% |
---|---|
Return on equity | 7.55% |
Return on investment | 7.16% |
More ▼
Cash flow in USDView more
In 2024, cash reserves at Supernus Pharmaceuticals Inc fell by 5.72m. However, the company earned 171.95m from its operations for a Cash Flow Margin of 25.98%. In addition the company generated 12.19m cash from financing while 189.87m was spent on investing.
Cash flow per share | 2.76 |
---|---|
Price/Cash flow per share | 11.59 |
Book value per share | 18.58 |
---|---|
Tangible book value per share | 7.12 |
More ▼
Balance sheet in USDView more
Current ratio | 2.35 |
---|---|
Quick ratio | 2.16 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | -8.87 |
---|---|
EPS (TTM) vs TTM 1 year ago | 8,784.85 |